Plain-English translation of NCT07017816 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called that delivers a healthy gene directly into cancer cells, along with an immunotherapy drug called and radiation therapy. The study is for children whose brain tumors have returned or stopped responding to standard treatments. Researchers want to find the right dose of this three-part treatment and understand how safe and effective it is.
Children with recurrent or treatment-resistant brain tumors have very few options left, and most standard treatments have not worked for them. This medication is designed to work in a new way—by replacing a faulty gene in cancer cells—and combining it with immunotherapy and radiation may help fight these aggressive tumors more effectively.
You likely qualify if…
You likely don't qualify if…
In the first treatment cycle, you will receive the medication twice a week, the immunotherapy drug every 2 weeks, and radiation therapy during week 2. In later cycles, the schedule adjusts—sometimes you'll receive the medication once per week, sometimes twice per week, with the immunotherapy drug continuing every 2 weeks. A small group of participants will also have tumor samples tested genetically after receiving the medication. The trial involves regular clinic visits, blood work, scans, and close monitoring for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States